Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Inclusion Criteria:

Lack of a human leukocyte antigen (HLA) matched related donor, lack of an immediately available 8/8 HLA matched unrelated donor
Patients must be diagnosed with a high-risk and/or advanced hematologic malignancy defined as one of the following
Acute lymphocytic leukemia (ALL) in complete remission (CR)1 with high-risk features including adverse cytogenetic such as t(9;22), t(1;19), t(4;11), or MLL gene rearrangements; in second or greater morphologic remission; persistent minimal residual disease
Acute myeloid leukemia (AML) in CR1 with intermediate-risk disease and persistent detectable minimal residual disease (MRD), or with high-risk features defined as: greater than 1 cycle of induction therapy required to achieve remission; preceding myelodysplastic syndrome (MDS) or myeloproliferative disease; presence of FLT3 mutations or internal tandem duplications, DNMT3a, TET2, MLL-partial tandem duplication (PTD), ASXL1, PHF6; FAB M6 or M7 classification; adverse cytogenetics including: -5, del 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8, complex (> 3 abnormalities)
Patients with AML must have less than 10% bone marrow blasts and < 100/mcL absolute peripheral blood blast count
Patients with AML in CR2, subsequent CR or with active disease at transplant (< 10% bone marrow blasts)
MDS with International Prognostic Scoring System (IPSS) intermediate-2 or higher, therapy-related MDS or chronic myelomonocytic leukemia (CMML)
Aplastic anemia with absolute neutrophil count (ANC) < 1,000 and transfusion dependent after failed immunosuppression therapy
Chronic myeloid leukemia (CML) >= 1st chronic phase, after failed >=2 lines of tyrosine kinase inhibitors; patients who progressed to blast phase must be in morphologic remission at transplant
Relapsed Hodgkin's disease or non-Hodgkin's lymphoma (NHL)
Patients with chemo-sensitive chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with persistent or recurrent disease after fludarabine-based regimens with < 25% involvement by CLL/SLL cells
Patients with lymphoblastic lymphoma in remission or after partial response to chemotherapy
Patients with poor prognosis multiple myeloma by cytogenetics del13, del 17p, t(4;14) or t(14;16) or hypodiploidy, with advanced disease (stage >= 2) and /or relapsed after autologous stem cell transplant
Zubrod performance status 0-1 or Karnofsky performance status > 70%; patients > 50 years will have to have a Sorror Comorbidity Index =< 3
Available haploidentical donor willing and eligible to undergo a peripheral blood collection
Left ventricular ejection fraction (LVEF) > 40%
Bilirubin =< 1.5 mg/dl (unless Gilbert's syndrome), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 200 IU/ml for adults; conjugated (direct) bilirubin < 2 x upper limit of normal
Serum creatinine clearance >= 50 ml/min (calculated with Cockcroft-Gault formula)
Diffusing capacity for carbon monoxide (DLCO) >= 45% predicted corrected for hemoglobin
Patient or patient's legal representative must provide written informed consent

Exclusion Criteria:

Human immunodeficiency virus (HIV) positive; active hepatitis B or C
Patients with active infections; the principal investigator (PI) is the final arbiter of the eligibility
Liver cirrhosis with greater than grade 1 stage 1 inflammation/fibrosis
Uncontrolled central nervous system (CNS) involvement by tumor cells within the past 2 months
History of another primary malignancy that has not been in remission for at least 3 years; (the following are exempt from the 3-year limit: nonmelanoma skin cancer, fully excised melanoma in situ [stage 0], curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear)
Positive beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization
Inability to comply with medical therapy or follow-up